Drug or intervention
Rifampin Clinical Trials
Studies that test Rifampin, alone, with other treatments or as the comparison.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 109Leprosy, Multibacillary
Telacebec in Adults With Multibacillary Leprosy (TEBULA Leprosy Trial)
The goal of this clinical trail is to evaluate whether short-course telacebec-based regimens can induce rapid and measurable reductions in M.
- Trial name
- TEBULA LEPROSY (NCT07918573)
- Testing
- Telacebec 300 mg, Telacebec 600 mg, Telacebec + Rifampicine
- Where
- Benin
- Volunteers
- 120 people
- Sponsor
- Fondation Raoul Follereau
Mycobacterium Avium Complex Pulmonary Disease
Short-term Bactericidal Effect of Contezolid in MAC-PD
The goal of this clinical trial is to learn if contezolid works to treat mycobacterium avium complex pulmonary disease in adults. It will also learn about the safety of contezolid.
- Trial name
- CONTE-MAC (NCT07084402)
- Testing
- Contezolid, Azithromcyin, Rifampicin (RIF)
- Where
- 3 sites in China
- Volunteers
- 188 people
- Sponsor
- Bin Cao
Mycobacterium Avium Complex Pulmonary Disease
Short-term Antibiotic Therapy in Mycobacterium Avium Complex Pulmonary Disease
The goal of this clinical trial is to learn if adding contezolid works to shorten the length of treatment in mycobacterium avium pulmonary disease in adults. It will also learn about the safety of extended usage of contezolid.
- Trial name
- NCT07213765
- Testing
- Contezolid, Azithromycin, Ethambutol (E)
- Where
- 6 sites in China
- Volunteers
- 188 people
- Sponsor
- Bin Cao
Tuberculosis
Re-evaluating the Duration in Children of TB Treatment
Current tuberculosis (TB) treatment is effective (works well), but it takes a long time to cure TB. This study will evaluate if TB treatment with a higher dose of rifampicin, one of the TB medicines, and shorter TB treatment…
- Trial name
- REDUCE TB (NCT07656012)
- Testing
- Rifampicin, Isoniazid, Pyrazinamide
- Where
- Peru
- Volunteers
- 230 people
- Sponsor
- University of Wisconsin, Madison
Mycobacterium; Xenopi, Lung Diseases
Amikacin Liposome Inhalation Suspension for Treatment of Mycobacterium Xenopi Pulmonary Infection
Treatment of Mycobacterium xenopi (MX) lung disease is not-well- tolerated and concerned a growing number of patients, especially with chronic pulmonary diseases or immunosuppression.
- Trial name
- AKAPI (NCT06585020)
- Testing
- Arikayce, standard treatment
- Where
- France
- Volunteers
- 190 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Tuberculosis (TB)
Optimal Treatment Duration for Radiographically Apparent, Bacteriologically Unconfirmed TB, Identified Through Active Case Finding (RADIO-TB Trial)
People living in high TB burden communities who undergo active case finding for TB may have chest X-ray changes suggestive of TB but their sputum test can be negative for the TB bacteria or they are unable to provide a sputum…
- Trial name
- RADIO-TB (NCT07163143)
- Testing
- Isoniazid (H), Rifampicin (R), Pyrazinamide (Z)
- Where
- 4 sites in Pakistan, South Africa and 1 more
- Volunteers
- 784 people
- Sponsor
- University College, London
Rifampicin-Resistant Pulmonary Tuberculosis, Multidrug-Resistant Pulmonary Tuberculosis
A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis
This is a Phase 3, randomized, open-label, active-controlled, multicenter trial evaluating the efficacy, safety, and tolerability of quabodepistat-containing regimens for the treatment of rifampicin-resistant or…
- Trial name
- QUANTUM-TB (NCT07209761)
- Testing
- Bedaquiline, Quabodepistat, Pretomanid
- Where
- 42 sites in China, Georgia and 8 more
- Volunteers
- 532 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Drug Resistant Tuberculosis
Bring BPaL2Me Trial Comparing Nurse-Led RR-TB Treatment to Physician-Led RR-TB Treatment
The goal of the BringBPaL2Me Trial, a multi-principal investigator, multi-site, cluster randomized, non-inferiority trial is to compare nurse-led RR-TB treatment in primary care clinics to standard of care physician-led RR-TB…
- Trial name
- NCT05671718
- Testing
- Nurse-Led Treatment in Primary Care
- Where
- 5 sites in South Africa
- Volunteers
- 2,944 people
- Sponsor
- Johns Hopkins University
Non-Puerperal Mastitis
Ablation Versus Non-ablation Strategies for Non-puerperal Mastitis: A Prospective Real-world Registry Study
The goal of this prospective registry cohort study is to evaluate the efficacy and quality-of-life impact of ablation therapy in patients with non-puerperal mastitis.
- Trial name
- NCT07894614
- Testing
- Ablation, Observation
- Where
- China
- Volunteers
- 340 people
- Sponsor
- Song Hongping
Healthy Adult Participants
A Phase 1 Multiple Dose Trial in Healthy Adult Participants to Evaluate the Safety, Tolerability, Drug-Drug Interactions, and Pharmacokinetics of TBD11
This is a Phase 1, randomized, double-blind, placebo-controlled, multiple dose trial of TBD11 in healthy adults. It includes a dedicated open-label cohort in which TBD11 will be administered as a single dose with either a strong…
- Trial name
- NCT07883226
- Testing
- TBD11 (300 mg), Itraconazole (200 mg), Rifampicin 600mg
- Where
- South Africa
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Gates Medical Research Institute
Completed, with results posted
All 106Tuberculosis
Tuberculosis Treatment Shortening Trial
Tuberculosis (TB) is a serious infection that can affect the lungs and other parts of the body. The usual way to treat TB is to take 4 medicines by mouth every day for 2 months, then take 2 of the same medicines for 4 more…
- Trial name
- NCT00130247
- Testing
- Ethambutol, Isoniazid, Pyrazinamide
- Where
- 3 sites in Brazil, Philippines and 1 more
- Volunteers
- 394 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Healthy Volunteers
A Study of Soticlestat and Rifampin in Healthy Adults
The main aim of this study is to check how rifampin affects the way soticlestat is processed by the body. Participants will be required to stay at the study clinic for 18 consecutive days.
- Trial name
- NCT05098041
- Testing
- Soticlestat, Rifampin
- Where
- United Kingdom
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Takeda
Pulmonary Tuberculoses, Other Specified Pulmonary Tuberculosis
BTZ-043 - Multiple Ascending Dose (MAD) to Evaluate Safety, Tolerability and Early Bactericidal Activity (EBA)
This is a prospective, open label, two-centre, randomized, controlled, two-stage, phase Ib/IIa study to evaluate the safety, tolerability, PK, drug-drug interaction and bactericidal activity of BTZ-043 administered orally once…
- Trial name
- NCT04044001
- Testing
- BTZ-043, Rifafour e-275®, Probe Drug Cocktail
- Where
- 2 sites in South Africa
- Volunteers
- 78 people
- Sponsor
- Michael Hoelscher
Tuberculosis
Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis
The Tuberculosis Trials Consortium (TBTC) Study 31 is a phase 3 trial evaluating rifapentine-containing regimens for treatment-shortening of drug-susceptible pulmonary tuberculosis.
- Trial name
- S31PK/PD (NCT02563327)
- Testing
- Rifapentine, Moxifloxacin, Rifampin
- Where
- 3 sites in United States, Uganda and 1 more
- Volunteers
- 2,516 people
- Sponsor
- Centers for Disease Control and Prevention
Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant
Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients
To evaluate the efficacy, safety and tolerability at 8 weeks (2-months), 52 weeks (12-months), and 104 Weeks (24-months) post the start of the following treatment regimens in participants with: Drug Sensitive TB (DS-TB) patients…
- Conditions
- Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant, Tuberculosis, MDR, Tuberculosis
- Trial name
- NCT03338621
- Testing
- Pretomanid, Bedaquiline, Moxifloxacin
- Where
- 26 sites in Brazil, Georgia and 6 more
- Volunteers
- 455 people
- Sponsor
- Global Alliance for TB Drug Development